Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Global Foot Insoles Market 2017-2021

Due to its structural nature, the human foot is intended to walk on natural grounds and without the use of high heels. The unusual inclined position of the foot due to heels and often flat floor will result in damage to the foot and therefore, in the podalgia. Most humans are born with healthy feet. Damage to the feet predominantly develops with time. The causes are disposition, overweight, hard grounds, wrong footwear, sport injuries, rheumatic changes, circulatory disorders, and neuropathies. The analysts forecast global foot insoles market to grow at a CAGR of 6.64% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global foot insoles market for 2017-2021. To calculate the market size, the report considers......
$3500

Global Protein Therapeutics Market 2017-2021

Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins. The analysts forecast global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate th......
$3500

Global Infantile Spasms Therapeutics Market 2017-2021

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox-Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy. The analysts forecast global infantile spasms therapuetics market to grow at a CAGR of 1......
$3500

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth. The analysts forecast global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs. The market is divided......
$3500

Global Cancer Monoclonal Antibodies Market 2017-2021

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics. The analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021. Covered in this report This report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, This report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be......
$3500

Global Multiple Myeloma Drugs Market 2017-2021

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require. The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during ......
$3500

Global Smart Healthcare Market 2016-2020

Smart healthcare is the integration of different healthcare delivery mechanisms. It makes use of electronic patient records and streamlining processes, which leads to improved quality of life by reducing the risks to health (by remote monitoring and checks) and improving the general well-being of people. Smart healthcare provides more patient-centric services that improves access to healthcare and are customized to individual patients' needs. The analysts forecast global smart healthcare market to grow at a CAGR of 24.55% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global smart healthcare market for 2016-2020. To calculate the market size, the report considers the revenue generated from solutions EHR, ......
$2500

Nurse Call System Market in the US 2016-2020

The NCS helps a caregiver and a patient to effectively communicate with each other and enhance patient care. In the US, individuals undergoing treatment in specialized healthcare facilities such as in SNFs, ALFs, and ACFs need constant attention and care. Hence, to provide 24/7 care to them, there is a need for a dedicated line of communication between patients and caregivers; NCS are used for this purpose. The analysts forecast nurse call system market in the US to grow at a CAGR of 14.18% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the nurse call system market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of NCS, including nurse call comp......
$2500

Global Pompe Disease Treatment Market 2016-2020

Lysosomal storage diseases (LSDs) are a group of progressive, autosomal recessive, and hereditary disorders characterized by the accumulation of specific substrates and variable age of onset and clinical symptoms. Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action (MOA) of GAA; it is an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen to toxic levels in the lysosomes of the cells. The buildup of glycogen in certain tissues and organs, especially in the muscles, hinders the normal functions of the organs. It can be further divided as adult-onset and infantile-onset Pompe diseases. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and pass one copy of th......
$2500

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system. The analysts forecast global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects o......
$2500